QPEX BIOPHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-10-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.qpexbio.com
Clinical Trials
8
Active:0
Completed:6
Trial Phases
1 Phases
Phase 1:8
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (100.0%)A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Bacterial Infections
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06547554
- Locations
- 🇺🇸
Minneapolis Clinic, Minneapolis, Minnesota, United States
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
Phase 1
Completed
- Conditions
- Bacterial Infections
- Interventions
- Drug: Xeruborbactam Oral Prodrug
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06157242
- Locations
- 🇺🇸
University of Miami Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants
Phase 1
Recruiting
- Conditions
- Bacterial Infections
- Interventions
- Drug: Xeruborbactam Oral ProdrugDrug: Xeruborbactam Oral Prodrug Placebo
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT06079775
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05072444
- Locations
- 🇺🇸
Altasciences, Cypress, California, United States
SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers
Phase 1
Completed
- Conditions
- Bacterial Infections
- Interventions
- Drug: Placebo for IV infusionDrug: QPX9003 for IV Infusion
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04808414
- Locations
- 🇺🇸
Altasciences, Cypress, California, United States
- Prev
- 1
- 2
- Next
News
No news found